ClinicalTrials.gg
CompletedNCT02914665Updated Jul 28, 2020

A Phase 2 Study to Evaluate the Cardiac and Renal Effects of Short Term Treatment With Elamipretide in Patients Hospitalized With Congestion Due to Heart Failure

A Phase 2 interventional study of elamipretide and Placebo in Heart Failure, sponsored by Stealth BioTherapeutics Inc.. Completed at 46 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-07-28.

Sponsored by Stealth BioTherapeutics Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
308
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 341 studies in Heart Failure with a site in Spain — 76 open to participants now, 98 under way, 21 of them phase 3. Heart Failure · Spain.

Enrollment
125th of 263
308 · median 294
Started
2016
with 12 others
Phase 2
38 of 341
5 open now
Registered
124th of 341
by date

Among the 341 studies in Heart Failure with a site in Spain, this one is the 125th largest by enrollment of the 263 interventional ones that give a count, is one of 13 that started in 2016, is one of 38 in phase 2, and was the 124th registered.

Heart Failure

6,332 studies on the registry are indexed under Heart Failure; 1,394 are open to participants now.

Browse Heart Failure studies →

Open to participants now

76 of the 341 studies in Heart Failure with a site in Spain are open now. Recruiting first, the newest first:

71 more — sign in →

All 76 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 967 Heart Failure studies recruiting now, 690 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 341 studies in Heart Failure with a site in Spain, or all of them as a file.
02

Study summary

This is a phase 2 randomized, double-blind, placebo-controlled study to evaluate the cardiac and renal effects of short term treatment with elamipretide in patients hospitalized with congestion due to heart failure

03

Conditions studied

  • Heart Failure

Keywords

  • Heart failure
  • diuresis
  • dropsy
  • congestion
  • elamipretide
  • MTP-131
  • Bendavia™
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A history of chronic heart failure for at least 1 month
  • Treated with ≥40 mg/day of furosemide or bumetanide ≥1 mg/day or torasemide ≥10 mg/day for at least 1 month
  • In-hospital observation/admission and treatment for ≤72 hours and primary cause for admission is heart failure with persistent congestion in the opinion of the Investigator (i.e. at least +2 pitting oedema and/or an estimated 8 kg gain in weight over baseline over the past 4 weeks) requiring intravenous loop diuretic therapy
  • Sufficiently severe oedema to justify treatment by an intravenous infusion of furosemide of 10 mg/hour for at least 48 hours
  • Systolic blood pressure >90 mmHg and considered to be haemodynamically stable, in the opinion of the Investigator
  • History of (LVEF) ≤40% confirmed in the last 18 months
  • NT-proBNP >1500 pg/ml or BNP >500 pg/ml
  • An of >30 mL/min/1.73 m2 using the eGFR (mL/min/1.73 m2) = 175 x (Scr)-1.154 x (Age)-0.203 x (0.742 if female) x (1.212 if African American)

Exclusion criteria

Exclusion Criteria:

  • Acute coronary syndrome, stroke, or (TIA), coronary or peripheral revascularization procedures, valve procedures, OR any major surgical procedure within the previous 6 weeks
  • Invasive cardiac investigation and/or treatment (i.e. coronary angiography, percutaneous coronary intervention [PCI] or surgery) or other surgical procedure planned in the next 4 weeks
  • Use of intravenous radiographic contrast agent within 72 hours prior to screening or planned use during the study
  • Severe, in the investigators opinion, uncorrected valve disease or congenital heart disease as the cause for cardiac decompensation
  • Acute mechanical cause of decompensated heart failure such as papillary muscle rupture
  • Obstructive or infiltrative cardiomyopathy (e.g. amyloid, sarcoid, etc), suspected acute myocarditis, or heart failure related to an untreated metabolic condition (e.g. haemochromatosis)
  • Second or third degree heart block unless the subject has a ventricular pacemaker
  • Atrial fibrillation/flutter with sustained ventricular response of >130 bpm
  • Placement of a ventricular resynchronization device within the previous 6 weeks
  • Treatment or planned treatment with intravenous inotropic agents other than digoxin at any time on this admission
  • Receipt of intravenous vasodilator therapy ≤ 6 hours prior to randomization
  • The presence of any mechanical assist device or listed for or a history of a heart transplant
  • Severe respiratory disease or anticipated need for mechanical respiratory support (i.e. mechanical ventilation)
  • Anuric in the previous 24 hours
  • \<9 g/dL at screening or planned blood transfusions in the next 30 days
  • Serum potassium >5.5 mEq/L
  • Marked proteinuria suggestive of nephrotic syndrome
  • Estimated (eGFR) as per MDRD equation \<30 ml/min
  • Serum albumin of \< 2.8 g/dL
  • Liver enzymes ( [ALT] and/or aspartate aminotransferase [AST]) elevation >5 times the (ULN)
  • Total >2.0 times ULN in the absence of Gilbert's Syndrome
  • Current or planned ultrafiltration, paracentesis, haemofiltration or dialysis
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
308 participants (actual)

Study arms

  • Experimental
    20 mg elamipretide

    20 mg elamipretide once daily for 7 consecutive days

    Drug: elamipretide

  • Placebo comparator
    Placebo

    Placebo once daily for 7 consecutive days

    Drug: Placebo

Interventions

  • 20 mg elamipretide administered intravenously once daily for 7 consecutive days

    Also known as: MTP-131, Bendavia

  • DrugPlacebo

    Placebo administered intravenously once daily for 7 consecutive days

06

What researchers measure

Primary outcomes

  1. Change in NT-proBNP between Baseline and Day 8/Early Discharge

    Time frame: Baseline to Day 8

Secondary outcomes

  1. Number of patients staying in the same functional renal function class measured with MDRD formula compared to the number of patients with decreasing or increasing renal function measured with MDRD formula

    Time frame: Baseline to Day 3 and Day 8

  2. Number of patients showing a decrease in body weight compared to baseline as well as number of patients showing either no decrease or an increase in body weight compared to baseline

    Time frame: Baseline to Day 3 and Day 8

  3. Calculation of decrease or increase in body weight normalised to the average dose (in mg) of furosemide administered

    Time frame: Baseline to Day 3 and Day 8

  4. The patient and physician global assessment is a 7-point scale which either the patient or the physician will assess from 0 to 10 and will be mathematically averaged on a daily basis in order to compare the different averages throughout the study.

    Time frame: Baseline to Day 3 and Day 8

  5. The average daily dose of diuretic (furosemide - adjusted for thiazide dose if administered) between baseline and Day 3 and Day 8/Early Discharge

    Time frame: Baseline to Day 3 and Day 8

  6. All adverse events, serious adverse events and SUSARs will be summarised per treatment group, namely elamipretide versus placebo, and compared at the end of the study.

    Time frame: Baseline to Day 8

  7. Half-life (T1/2)

    Time frame: Baseline to Day 8

  8. Area under the concentration - time curve from 0-24 h (AUC 0-24)

    Time frame: Baseline to Day 8

  9. Area under the concentration - time curve from 0- infinity (AUC 0-∞)

    Time frame: Baseline to Day 8

  10. Peak Plasma Concentration (Cmax)

    Time frame: Baseline to Day 8

07

Study locations

46 sites
  • Hospital Onze Lieve Vrouw campus Aalst
    Aalst, 9300, Belgium
  • Hospital ZNA Middelheim
    Antwerp, 2020, Belgium
  • Department of Internal Diseases, "Multiprofile Hospital for Active Treatment Sveta Ekaterina - Dimitrovgrad" EOOD
    Dimitrovgrad, 6400, Bulgaria
  • Clinic of Cardiology, "Second Multiprofile Hospital for Active Treatement - Sofia" EAD
    Sofia, 1202, Bulgaria
  • Clinic of Cardiology, Multiprofile Hospital for Active Treatment National Heart Hospital" EAD
    Sofia, 1309, Bulgaria
  • Clinic of Cardiology, "City Clinic University Multiprofile Hospital for Active Treatment" EOOD
    Sofia, 1407, Bulgaria
  • Clinic of Internal Diseases, "Multiprofile Hospital for Active Treatment, "Sveta Anna Sofia" AD
    Sofia, 1750, Bulgaria
  • Department of Cardiology, "Multiprofile Regional Hospital for Active Treatement Dr. Stefan Cherkezov" AD
    Veliko Tarnovo, 5000, Bulgaria
  • Hôpital Henri Mondor
    Créteil, 94000, France
  • CHU de Rangueil
    Toulouse Cedex 9, 31059, France
  • Hungarian Institute Of Cardiology, Department of Adult Cardiology
    Budapest, 1096, Hungary
  • Semmelweis University Heart and Vascular Center
    Budapest, 1122, Hungary
  • County St. George University Teaching Hospital, Department of Internal Medicine Cardiology
    Székesfehérvár, 8000, Hungary
  • Zala County Hospital Cardiology Department
    Zalaegerszeg, 8900, Hungary
  • Daugavpils Regional Hospital
    Daugavpils, LV5417, Latvia
  • Riga East Clinical University Hospital, Clinic Gailezers
    Liepaja, LV1038, Latvia
  • Liepaja Regional Hospital
    Liepaja, LV3402, Latvia
  • Pauls Stradins Clinical University Hospital, Latvian Centre of Cardiology
    Riga, LV1002, Latvia
  • Deventer Hospital
    Deventer, 7416 S, Netherlands
  • Hospital Gelderse Vallei
    Ede, 6716 RP, Netherlands
  • University Medical Center Groningen
    Groningen, 9713 GZ, Netherlands
  • Hospital Jeroen Bosch
    Hertogenbosch, 5223 GV 's, Netherlands
  • Hospital Antonius/D&A research Genetic
    Sneek, 8601 ZR, Netherlands
  • Hospital Elisabeth -Tweesteden
    Tilburg, 5042 AD, Netherlands
  • Hospitals Gelre
    Zutphen, 7207 AE, Netherlands
  • Bieganski Provincial Specialist Hospital, Department of Cardiology, Clinic of Cardiology UM
    Lodz, 91-347, Poland
  • Cardinal Stefan Wyszynski, Institute of Cardiology, Clinic Heart Failure and Transplantation
    Warsaw, 04-628, Poland
  • Cardinal Stefan Wyszynski, Institute of Cardiology, Clinic of Coronary Heart Disease and Structural Heart Disease
    Warsaw, 04-628, Poland
  • Clinical Centre of Serbia, Emergency Centre
    Belgrade, 11000, Serbia
  • Clinical Centre of Serbia, Institute for Cardiovascular Diseases
    Belgrade, 11000, Serbia
  • Clinical Hospital Centre Bezanijska kosa
    Belgrade, 11070, Serbia
  • Clinical Hospital Centre Zemun
    Belgrade, 11080, Serbia
  • Clinical Centre Nis
    Nis, 18000, Serbia
  • Institute for Cardiovascular Diseases of Vojvodina
    Sremska Kamenica, 21204, Serbia
  • Hospital Universitario de Bellvitge
    Barcelona, 08907, Spain
  • Complexo Hospitalario Universitario de A Coruña
    Coruña, 15006 A, Spain
  • Hospital General Universitario Gregorio Marañón
    Madrid, 28007, Spain
  • Hospital Clínico San Carlos
    Madrid, 28040, Spain
  • Hospital Universitario Puerta de Hierro Majadahonda
    Madrid, 28222 Majadahonda, Spain
  • Hospital Alvaro Cunqueiro
    Pontevedra, 36312 Vigo, Spain
  • Hospital Clínico Universitario de Valencia
    Valencia, 46010, Spain
  • Consorci Hospital General Universitari de Valencia
    Valencia, 46014, Spain
  • Hospital Universitari i Politècnic La Fe
    Valencia, 46026, Spain
  • Bradford Royal Infirmary
    Bradford, BD6 6RJ, United Kingdom
  • Glenfield Hospital
    Leicester, LE3 9QP, United Kingdom
  • Torbay Hospital
    Torquay, TQ2 7AA, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2016 to primary completion in Nov 2017, 13 months.

Of 74 industry-sponsored phase 2 interventional studies under Heart Failure, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 31. This study's 13 months is below that.

Counting every sponsor, half of 185 studies reached it within 29 months; a quarter within 17 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2016
First posted
Sep 26, 2016
StartActual
Oct 20, 2016
Primary completionActual
Nov 27, 2017
CompletionActual
Nov 27, 2017
Last update
Jul 28, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 28, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02914665
Responsible party
Sponsor
First posted
Sep 26, 2016
Start date
Oct 20, 2016
Primary completion
Nov 27, 2017
Completion
Nov 27, 2017
Last update
Jul 28, 2020

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Elamipretide

Start the discussion